Tuesday, October 13, 2009

Call for papers for Advances in Tumor Virology from Dr Frank J Jenkins

Dear colleagues,

Our understanding of the role of viruses in tumor formation both in animals as well as humans has grown substantially over the last 10-20 years. Until now, there has not been a journal focused solely on the field of tumor virology. Advances in Tumor Virology (ATV) represents a unique, first of its kind journal that publishes articles relevant to all aspects of virus-induced carcinogenesis. ATV is an open access journal and therefore can reach a broad audience that is not restricted only to individuals or institutions with subscriptions.

The most difficult aspect of starting a new journal is getting scientists in the field to submit papers during the journal’s infancy. Even though the journal was started in August of 2009, within two months the journal’s web site has received over 6,200 hits. This is a testament to the need for ATV in cancer virology and demonstrates the interest of scientists all over the world in this journal. I encourage you to give serious consideration to submitting a paper to ATV. I know you will find the review process refreshing with each article reviewed by at least two knowledgeable experts in the field. I am absolutely convinced that as this journal proceeds, it will become a leading journal in this field.

What is the advantage to you of publishing in Advances in Tumor Virology?
  • Full open access: everyone can read your article and you retain copyright in it
  • Publishing decision within 2 weeks of submission
  • Your paper will not be rejected due to lack of space and will be published immediately on acceptance
  • Prompt and fair peer review from two expert peer reviewers
  • Frequent updates on your paper’s status
  • Friendly responsive staff
What a previous author said:
"The publishing process of this journal was a most pleasant and productive experience. I was particularly impressed with the regular updates of the progress of my submission. Many other journals receive a submission and authors may not hear anything for months. I appreciate your notification policy."
In summary:

The advantages of a younger journal such as Advances in Tumor Virology are numerous but in essence allow us a greater flexibility and responsiveness to authors and readers that older journals cannot match.

Next steps:


Yours sincerely,
Dr Frank J Jenkins

Editor-in-Chief
Advances in Tumor Virology